Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant
September 14 2020 - 10:06AM
Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage
biopharmaceutical company dedicated to the discovery and
development of novel therapeutics to treat cystic fibrosis and
other diseases caused by nonsense mutations limiting production of
functional proteins, today announced that Professor Eitan Kerem,
M.D. has joined the Company as a Senior Consultant. Dr.
Kerem will continue to advise on our cystic
fibrosis program focusing on strategic leadership, cystic fibrosis
medical safety review, and medical communications, as well as
liaising with patient advocacy groups and regulatory authorities.
“We are very pleased to welcome to Eloxx someone of
Dr. Kerem’s caliber and recognized expertise in cystic
fibrosis as we advance our Phase 2 proof of concept clinical trial
program for ELX-02 in patients with nonsense mediated cystic
fibrosis, for whom a high unmet medical need exists,” said Dr.
Gregory Williams, Chief Executive Officer of Eloxx Pharmaceuticals.
“We believe that Dr. Kerem’s vast experience in cystic fibrosis
will provide us with critical counsel as we approach a substantial
value inflection point for our Company. It is our highest priority
to report top line results from our Phase 2 clinical trial program
as soon as feasible.”
Dr. Kerem joined Eloxx on September 1st upon his
retirement from Hadassah Medical Center where he most recently
served as Head of Pediatrics and Professor of Pediatrics at Hebrew
University Hadassah Medical School. Dr. Kerem was a board member of
the European Cystic Fibrosis Society where he contributed to the
development of the European Cystic Fibrosis Registry and was the
President of CIPP, the Annual International Congress on
Pediatric Pulmonology. Dr. Kerem was previously a
member of the editorial boards of the leading journals in the field
of pulmonology, “Pediatric Pulmonology”,
"Chest" and the “American Journal of
Respiratory and Critical Care Medicine”.
Dr. Kerem has been intimately involved with ELX-02 and the
Eloxx team since 2015, originally working with Professor Timor
Baasov at the Technion Institute to optimize ELX-02 in the early
stages of its development. He is a
globally renowned cystic fibrosis Key Opinion Leader and
has helped guide Eloxx through the development of our
clinical trial program. Dr. Kerem serves on our Cystic
Fibrosis Medical Advisory Board, has been the Global Lead
Investigator for our Phase 2 cystic fibrosis clinical trial program
and had served as Chairman of the Safety Review
Committee.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company developing novel RNA-modulating drug
candidates (designed to be eukaryotic ribosomal selective
glycosides) that are formulated to treat rare and ultra-rare
premature stop codon diseases. Premature stop codons are point
mutations that disrupt protein synthesis from messenger RNA. As a
consequence, patients with premature stop codon diseases have
reduced or eliminated protein production from the mutation bearing
allele accounting for some of the most severe phenotypes in these
genetic diseases. These premature stop codons have been identified
in over 1,800 rare and ultra-rare diseases.
Read-through therapeutic development is focused on extending
mRNA half-life and increasing protein synthesis by enabling the
cytoplasmic ribosome to read through premature stop codons to
produce full-length proteins. Eloxx’s lead investigational product
candidate, ELX-02, is a small molecule drug candidate designed to
restore production of full-length functional proteins. ELX-02 is in
the early stages of clinical development focusing on cystic
fibrosis. ELX-02 is an investigational drug that has not been
approved by any global regulatory body. Eloxx’s preclinical
candidate pool consists of a library of novel drug candidates
designed to be eukaryotic ribosomal selective glycosides identified
based on read-through potential. Eloxx also has preclinical
programs focused on kidney diseases including autosomal dominant
polycystic kidney disease, as well as rare ocular genetic
disorders. Eloxx is headquartered in Waltham, MA, with operations
in Rehovot, Israel and Morristown, NJ. For more information,
please visit www.eloxxpharma.com.
Forward-Looking Statements This press
release contains forward-looking statements, which are generally
statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections,
and speak only as of the date they are made. We undertake no
obligation to update any forward-looking statement in light of new
information or future events, except as otherwise required by law.
Forward-looking statements involve inherent risks and
uncertainties, most of which are difficult to predict and are
generally beyond our control. Actual results or outcomes may differ
materially from those implied by the forward-looking statements as
a result of the impact of a number of factors, including: the
development of the Company’s read-through technology; the approval
of the Company’s patent applications; the Company’s ability to
successfully defend its intellectual property or obtain necessary
licenses at a cost acceptable to the Company, if at all; the
successful implementation of the Company’s research and development
programs and collaborations; the Company’s ability to obtain
applicable regulatory approvals for its current and future product
candidates; the acceptance by the market of the Company’s products
should they receive regulatory approval; the timing and success of
the Company’s preliminary studies, preclinical research, clinical
trials, and related regulatory filings; the ability of the Company
to consummate additional financings as needed; the impact of global
health concerns, such as the COVID-19 global pandemic, on our
ability to continue our clinical and preclinical programs and
otherwise operate our business effectively; as well as those
discussed in more detail in our Annual Report on Form 10-K and our
other reports filed with the Securities and Exchange
Commission.
Contact:
Barbara Ryan 203-274-2825
barbarar@eloxxpharma.com
SOURCE: Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Sep 2023 to Sep 2024